I am an outlier,
But I am happy.
Treatment to cure is every person with Hep C’s goal. When
things get closer to the end it can consume us to find the keys to the locked
exit doors. Even in my early 20s I gave up hope when Int/Riba failed, I grasped
at straws and took the treatment again with a higher dosage.
That grasping, failing, created my first RAV, I had a q80k
polymorphism. Failing a treatment is not simply continuing to have HCV but it
also bears the risk of creating mutations, RAVs.
So after failing Int/Rib/Incivek, Sovaldi/Olysio, Harvoni… I now have three mutations, RAVs.
Zepatier, the drug i’ve been waiting for had a contradiction I was worried about. While previously I was unsure my Child-Pugh score; I confirmed that it is
only A. Which means it shouldn’t be as hard to get access to the meds.
Daklinza/Sovaldi/Olysio/Riba is another contender.
(to make things even more complicated, the existence of RAVs from a previous
treatment does not indicate that the treatment will or will not necessarily
isn’t enough longitudinal data for my situation on these meds to make the best decision.
Why? Because breakthrough medications often lack the studies their non-breakthrough
partners have at date of FDA approval. Breakthrough therapies are not about the
results, they’re about maximizing the amount of time the patent is most
Zepatier will undoubtedly change the conversation about Hep
C meds due to its lower price point and high efficacy in smaller groups as well
as across Genotype 1 and 4. I fear that
this low price point will drive a “consumer’s” choice in treatment.
(Insurance agencies, Healthcare groups and Pharma companies make the real
choice between medications before you even see em… which means 1/3 of the
people deciding give a shit about the
patient. Fucking Trident has more support
from leading dentists.)
There are many combinations of Hep C meds for many different cases, each one
with different efficacies. (Sovaldi ranges from 84-96% depending on subtype.)
The best drug/therapy to treat should be set by relative efficacy, not by
That being said, my condition is stable, I don’t seem to be
getting worse, nor am I getting better. If I keep up the healthy changes I’ve
been making I may be able to stay where I am for a few years yet.
The key now is choosing the best treatment, which means
waiting for more data. Thankfully the EASL (aka the International Liver
Conference) is coming up next month, so we should have more information in the
In the meantime later this month I’ll be making a trip to
Portland and Seattle. Making stops in San Francisco, and Sacramento.
If you’re along the route, ping me!
This blog is for information purposes only. The content is not intended as medical advice, diagnosis, or treatment. Should you have a medical or dermatological problem, please consult with your physician. None of the information or recommendations on this website should be interpreted as medical advice.
All product reviews, recommendations, and references are based on the author’s personal experience and impressions using the products. All views and opinions are the author’s own.
This blog post may contain affiliate links. An affiliate link means we may earn a commission if you click on a link and make a purchase, without any extra cost to you.
Please see our Disclaimer for more information.